Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with type 1 diabetes, sending the company’s share price up by about 200%. The data “pave the way for a potentially transformative cure,” for a disease that affects more than 1.7 million Americans, Citi analysts wrote in a Jan. 8 note.
Sana, co-founders Sonja Schrepfer, PhD, and Tobias Deuse, PhD, are the UCSF inventors.